U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07726433) titled 'Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV' on July 20.
Brief Summary: This study is a prospective, single-arm, multicenter, exploratory clinical trial divided into a screening phase, a treatment phase, and a follow-up phase. The study aims to evaluate the efficacy and safety of foslorapitant palonosetron for injection in preventing nausea and vomiting caused by treatment with recanituzumab. All patients who meet the inclusion criteria and do not meet any exclusion criteria are eligible for enrollment in this study and are scheduled to receive targeted therapy, antiemetic treatment, and fo...